196 related articles for article (PubMed ID: 30649348)
1. Implications of altered O-glycosylation in tumour immune evasion.
Itano N
J Biochem; 2019 May; 165(5):387-390. PubMed ID: 30649348
[TBL] [Abstract][Full Text] [Related]
2. A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
Sutoh Yoneyama M; Tobisawa Y; Hatakeyama S; Sato M; Tone K; Tatara Y; Kakizaki I; Funyu T; Fukuda M; Hoshi S; Ohyama C; Tsuboi S
J Biochem; 2017 Jun; 161(6):479-492. PubMed ID: 28011817
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans.
Tsuboi S; Sutoh M; Hatakeyama S; Hiraoka N; Habuchi T; Horikawa Y; Hashimoto Y; Yoneyama T; Mori K; Koie T; Nakamura T; Saitoh H; Yamaya K; Funyu T; Fukuda M; Ohyama C
EMBO J; 2011 Jun; 30(15):3173-85. PubMed ID: 21712812
[TBL] [Abstract][Full Text] [Related]
4. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.
Suzuki Y; Sutoh M; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Habuchi T; Arai Y; Fukuda M; Ohyama C; Tsuboi S
Int J Oncol; 2012 Jun; 40(6):1831-8. PubMed ID: 22446589
[TBL] [Abstract][Full Text] [Related]
5. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
6. Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview.
Salatino M; Rabinovich GA
Methods Mol Biol; 2011; 677():355-74. PubMed ID: 20941621
[TBL] [Abstract][Full Text] [Related]
7. Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms.
Davicino RC; Eliçabe RJ; Di Genaro MS; Rabinovich GA
Int Immunopharmacol; 2011 Oct; 11(10):1457-63. PubMed ID: 21600310
[TBL] [Abstract][Full Text] [Related]
8. Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; D'Angelo L; Santoro A; Nuti M; Rahimi H; Rughetti A
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682991
[TBL] [Abstract][Full Text] [Related]
9. Rho GTPase Rac1: molecular switch within the galectin network and for N-glycan α2,6-sialylation/O-glycan core 1 sialylation in colon cancer in vitro.
André S; Singh T; Lacal JC; Smetana K; Gabius HJ
Folia Biol (Praha); 2014; 60(3):95-107. PubMed ID: 25056432
[TBL] [Abstract][Full Text] [Related]
10. Loss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation.
Antonopoulos A; Demotte N; Stroobant V; Haslam SM; van der Bruggen P; Dell A
J Biol Chem; 2012 Mar; 287(14):11240-51. PubMed ID: 22334653
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis.
Rodrigues JG; Balmaña M; Macedo JA; Poças J; Fernandes Â; de-Freitas-Junior JCM; Pinho SS; Gomes J; Magalhães A; Gomes C; Mereiter S; Reis CA
Cell Immunol; 2018 Nov; 333():46-57. PubMed ID: 29576316
[TBL] [Abstract][Full Text] [Related]
12. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Anderson P; Aptsiauri N; Ruiz-Cabello F; Garrido F
Cell Mol Immunol; 2021 Mar; 18(3):556-565. PubMed ID: 33473191
[TBL] [Abstract][Full Text] [Related]
13. Glycosylation and Antitumor Immunity.
Cadena AP; Cushman TR; Welsh JW
Int Rev Cell Mol Biol; 2019; 343():111-127. PubMed ID: 30712671
[TBL] [Abstract][Full Text] [Related]
14. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.
Valenzuela HF; Pace KE; Cabrera PV; White R; Porvari K; Kaija H; Vihko P; Baum LG
Cancer Res; 2007 Jul; 67(13):6155-62. PubMed ID: 17616672
[TBL] [Abstract][Full Text] [Related]
15. HLA-G and its KIR ligands in cancer--another enigma yet to be solved?
Urosevic M; Trojan A; Dummer R
J Pathol; 2002 Mar; 196(3):252-3. PubMed ID: 11857486
[TBL] [Abstract][Full Text] [Related]
16. Altered Glycosylation in Progression and Management of Bladder Cancer.
Wilczak M; Surman M; Przybyło M
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110670
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins.
Bax M; García-Vallejo JJ; Jang-Lee J; North SJ; Gilmartin TJ; Hernández G; Crocker PR; Leffler H; Head SR; Haslam SM; Dell A; van Kooyk Y
J Immunol; 2007 Dec; 179(12):8216-24. PubMed ID: 18056365
[TBL] [Abstract][Full Text] [Related]
18. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
19. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
20. Glycosylation in health and disease.
Reily C; Stewart TJ; Renfrow MB; Novak J
Nat Rev Nephrol; 2019 Jun; 15(6):346-366. PubMed ID: 30858582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
